血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂暴露与关键肝硬化相关结局的关联
该回顾性主动对照新使用者研究纳入退伍军人健康管理局的肝硬化患者,比较ACE-I/ARB与钙通道阻滞剂新使用者的结局。逆概率治疗加权Cox回归显示ACE-I/ARB暴露与死亡率降低相关(HR 0.70,95%CI 0.61-0.81,P<0.001),在代偿期肝硬化患者中与肝失代偿或肝细胞癌无显著关联。
要点
- ACE-I/ARB暴露与肝硬化患者全因死亡率降低相关(HR 0.70,95%CI 0.61-0.81,P<0.001)。
- 在代偿期肝硬化患者中,ACE-I/ARB与肝失代偿或肝细胞癌无显著关联。
- ACE-I/ARB与降低非肝脏/非心血管相关死亡率相关(病因特异性HR 0.49,95%CI 0.38-0.62,P<0.001),但与肝脏相关或心血管相关死亡率无关。
核心结论
- ACE-I/ARB暴露与死亡率降低相关,可能通过心血管及其他(肾脏、恶性肿瘤相关)机制。
- 在代偿期疾病患者中,ACE-I/ARB与肝失代偿或肝细胞癌无显著关联。
- 未来研究应识别从ACE-I/ARB暴露中获益的患者亚群。
研究设计与样本
- 回顾性、主动对照新使用者研究,纳入退伍军人健康管理局的肝硬化患者。
- 新开始使用ACE-I/ARB或钙通道阻滞剂(对照)的患者。
- 逆概率治疗加权平衡关键混杂因素,Cox回归评估ACE-I/ARB与死亡率、肝硬化失代偿和肝细胞癌(HCC)的关联。
- 探索性分析采用病因特异性竞争风险模型评估肝脏相关 vs 心血管(CV)相关 vs 非肝脏/非CV相关死亡率。
主要发现
- 共有904例ACE-I/ARB新使用者与352例钙通道阻滞剂新使用者。
- 逆概率治疗加权Cox回归中,ACE-I/ARB暴露与死亡率降低相关(HR 0.70,95%CI 0.61-0.81,P<0.001)。
- 在代偿期肝硬化患者中,ACE-I/ARB与肝失代偿或HCC无显著关联。
- 病因特异性风险模型显示ACE-I/ARB暴露与降低非肝脏/非CV相关死亡率相关(病因特异性HR 0.49,95%CI 0.38-0.62,P<0.001),但与肝脏相关或CV相关死亡率无关。
- 在Child-Turcotte-Pugh A患者中,ACE-I/ARB与降低CV相关死亡率相关(病因特异性HR 0.41,95%CI 0.26-0.65,P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) may have hepatic benefits in patients with primarily chronic liver disease. ACE-I/ARB have not been evaluated in broad cohorts inclusive of those with decompensated cirrhosis. We analyzed the real-world association between ACE-I/ARB exposure and cirrhosis-related outcomes in a national cohort. METHODS: We performed a retrospective, active comparator new user study of patients with cirrhosis in the Veterans Health Administration. We identified new initiators of ACE-I/ARB or calcium channel blockers (comparator). Inverse probability treatment weighting balanced key confounders and Cox regression evaluated the association between ACE-I/ARB and outcomes of mortality, cirrhosis decompensation, and hepatocellular carcinoma (HCC). In exploratory analysis, cause-specific competing risk models evaluated liver-related vs cardiovascular (CV)-related vs nonliver/non-CV-related mortality. RESULTS: There were 904 ACE-I/ARB and 352 calcium channel blocker new initiators. In inverse probability treatment weighting Cox regression, ACE-I/ARB exposure was associated with reduced mortality (hazard ratio [HR] 0.70, 95% confidence interval [CI] 0.61-0.81, P < 0.001). In patients with compensated cirrhosis, ACE-I/ARB were not associated with hepatic decompensation or HCC. Cause-specific hazard models showed ACE-I/ARB exposure was associated with reduction in nonliver/non-CV-related mortality (cause-specific HR 0.49, 95% CI 0.38-0.62, P < 0.001) but not liver-related or CV-related mortality. In Child-Turcotte-Pugh A patients, ACE-I/ARB were associated with decreased CV-related mortality (cause-specific HR 0.41, 95% CI 0.26-0.65, P < 0.001). DISCUSSION: ACE-I/ARB exposure was associated with reduced mortality, potentially through CV and other (renal, malignancy-related) mechanisms. In patients with compensated disease, ACE-I/ARB were not associated with hepatic decompensation or HCC. Future research should identify subsets of patients who benefit from ACE-I/ARB exposure.
引用
- Wang RX, Serper M, Taddei TH, et al. The Association Between Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Exposure and Key Cirrhosis-Related Outcomes. Am J Gastroenterol. 2024. PMID: 39051649. doi:10.14309/ajg.0000000000002976
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。